Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane/tazobactam in acute care inpatient facilities, Houston, Texas, USA

BACKGROUND: Ceftolozane/tazobactam is a β-lactam/β-lactamase inhibitor combination with activity against a variety of Gram-negative bacteria, including MDR Pseudomonas aeruginosa. This agent is approved for hospital-acquired and ventilator-associated bacterial pneumonia. However, most real-world out...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Truc T, Cabrera, Nicolo L, Gonzales-Luna, Anne J, Carlson, Travis J, Alnezary, Faris, Miller, William R, Sakurai, Aki, Dinh, An Q, Rydell, Kirsten, Rios, Rafael, Diaz, Lorena, Hanson, Blake M, Munita, Jose M, Pedroza, Claudia, Shelburne, Samuel A, Aitken, Samuel L, Garey, Kevin W, Dillon, Ryan, Puzniak, Laura, Arias, Cesar A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806660/
https://www.ncbi.nlm.nih.gov/pubmed/36601551
http://dx.doi.org/10.1093/jacamr/dlac131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806660/
https://www.ncbi.nlm.nih.gov/pubmed/36601551
http://dx.doi.org/10.1093/jacamr/dlac131

Ejemplares similares